Venus Remedies jumps on securing marketing authorization from Serbia for gemcitabine and docetaxel
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Venus Remedies is currently trading at Rs. 239.95, up by 6.75 points or 2.89% from its previous closing of Rs. 233.20 on the BSE.
The scrip opened at Rs. 240.90 and has touched a high and low of Rs. 241.00 and Rs. 239.95 respectively. So far 295 shares were traded on the counter.
The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 301.80 on 10-Jul-2023 and a 52 week low of Rs. 145.00 on 08-Feb-2023.
Last one week high and low of the scrip stood at Rs. 244.60 and Rs. 226.15 respectively. The current market cap of the company is Rs. 320.74 crore.
The promoters holding in the company stood at 41.76%, while Institutions and Non-Institutions held 0.98% and 57.26% respectively.
Venus Remedies has secured marketing authorization from Serbia for gemcitabine and docetaxel, widely used chemotherapy drugs beneficial in the treatment of various types of cancer. With this, the company has secured 511 marketing approvals for its oncology products across 66 countries.
Extending its reach in the Balkans and Eastern Europe, Venus Remedies secured a marketing authorization for gemcitabine from Bosnia a few months ago, which was followed by marketing approvals for docetaxel from Georgia and two other key cancer drugs from Moldova.
Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.
